New drug combo takes on deadly brain tumor
NCT ID NCT04656535
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a combination of two drugs (domvanalimab and zimberelimab) that aim to help the immune system fight glioblastoma, an aggressive brain cancer that has returned after initial treatment. About 46 participants will receive the drugs to check safety and see how the drugs affect the tumor and immune cells. The study is not yet testing whether the treatment improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Domvanalimab and zimberelimab (two immune-boosting drugs given together)
What this could lead to
If it works, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few effective therapies.
What could go wrong
This is a very early (phase 0/I) and small trial (46 people) focused on safety, not yet testing if the drugs actually shrink tumors or extend life. The combination may cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
Yale University
New Haven, Connecticut, 06519, United States